Integra LifeSciences stock tumbles after cutting 2026 outlook
Integra LifeSciences (IART) shares dropped 14% after cutting its 2026 revenue outlook to $1.634B-$1.654B and EPS to $2.30-$2.40 due to flooding at its Cincinnati facility. Q3 revenue is expected to be $410M-$412M, below estimates. The company expects insurance to cover some losses and maintains strong cash flow expectations.
How this was made
The 30-second read
Why it matters
The guidance cut triggered a sharp sell‑off, but the company’s strong cash flow outlook and upcoming refinancing may mitigate long‑term risk.
Market read
The news directly affects IART shareholders and may influence sentiment in the broader med‑tech sector.
What to watch
Insurance recoveries may offset a sizable portion of the earnings impact, and the new $600 M senior loan could improve liquidity.
Background
Integra LifeSciences reported a significant guidance downgrade after flood damage at its Cincinnati plant disrupted production.
Ticker impact
Integra LifeSciences cut its 2026 revenue and earnings guidance, causing a 14% share drop.
likely further downside as investors price in lower revenue and earnings
The company reduced full‑year revenue to $1.634‑$1.654 B and EPS to $2.30‑$2.40, below expectations, and the stock fell 14% on the news.
Market effects
Medical‑technology sector may see broader pressure as guidance cuts raise concerns about supply‑chain disruptions.
U.S. small‑cap healthcare stocks could face heightened volatility.
Limited to investors tracking U.S. med‑tech equities.
Counterpoint
The flood‑related disruption is temporary; the company expects full operations by Q2 2027, which could support a rebound.
Key entities
- companyIntegra LifeSciences Holdings
Medical‑technology firm that issued the guidance cut.
